KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomicsÂŽÂ discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer.âChris is an seasoned biotech finance executive who brings deep experience in the areas of corporate finance and operations with growing biopharma companies like KSQ,â said Qasim Rizvi, Chief Executive Officer of KSQ Therapeutics.
âWe are thrilled to have him join our team at this pivotal time in KSQâs growth trajectory.
Our CRISPRomics platform has expansive potential across therapeutic areas and modalities.
âThe company has shown its platform can discover and deliver on novel targets, and their recent progress and business development success is only the beginning.
I look forward to working with this dedicated team as they continue to develop next-generation cell therapies and novel therapeutics for both cancer and autoimmune disease.âMr.
Heberlig comes to KSQ with over 20 years of experience managing and leading teams, including overseeing the financial and operational responsibilities of private and publicly traded biotechnology companies.
KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomicsÂŽÂ discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer.âChris is an seasoned biotech finance executive who brings deep experience in the areas of corporate finance and operations with growing biopharma companies like KSQ,â said Qasim Rizvi, Chief Executive Officer of KSQ Therapeutics.
âWe are thrilled to have him join our team at this pivotal time in KSQâs growth trajectory.
Our CRISPRomics platform has expansive potential across therapeutic areas and modalities.
âThe company has shown its platform can discover and deliver on novel targets, and their recent progress and business development success is only the beginning.
I look forward to working with this dedicated team as they continue to develop next-generation cell therapies and novel therapeutics for both cancer and autoimmune disease.âMr.
Heberlig comes to KSQ with over 20 years of experience managing and leading teams, including overseeing the financial and operational responsibilities of private and publicly traded biotechnology companies.